Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694522 · ClinicalTrials.gov registry record · Phase 2
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
A Phase 2 study, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT03694522 is a Phase 2 study that has completed, run by Five Prime Therapeutics. The registered enrollment target is 155 participants.
The verdict
NCT03694522, a Phase 2 study, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
Interventions
- DRUG Placebo
- DRUG Modified FOLFOX6
- BIOLOGICAL Bemarituzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2022-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694522
The ClinicalTrials.gov registry entry for NCT03694522 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Five Prime Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03694522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03694522 about?
NCT03694522 is a clinical study titled "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer". The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
What is the current status of trial NCT03694522?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2018-09-14. Estimated completion is 2022-05-13.
What interventions are being tested in trial NCT03694522?
The interventions under investigation include: Placebo (DRUG), Modified FOLFOX6 (DRUG), Bemarituzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03694522?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.